Trending:

June 23, 2026, 03:00 PM - 6 min read
Human studies show that GLP-1 agonists reduce alcohol consumption. Preclinical animal studies suggest these drugs also reduce the use of cocaine, amphetamines, opiates and nicotine.
Read more
June 7, 2026, 01:51 PM - 6 min read
Beyond diabetes and obesity, GLP-1 drugs have now earned regulatory approval in several new areas. A trial of more than 17,000 people found semaglutide cut the risk of serious heart attacks and strokes by 20 per cent, even in people without diabetes.
Read more